Heartflow’s Campbell Rogers reports 111,412 shares sold
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Heartflow, Inc. (HTFL) Chief Medical Officer Campbell Rogers reported 111,412 shares sold across transactions dated February 20 through November 17, 2026. On November 17, he exercised options for 12,328 shares at $8.33 and 5,101 shares at $2.22. Sales that day included 24,188 directly held shares, 5,654 shares held by Campbell Rogers 2019 Irrevocable Trust, and 6,503 shares held by Spouse's Trust, each at $46.39 per share. Transactions were effected under Rule 10b5-1 plans adopted September 12, 2025, and June 16, 2026. A footnote for the 5,101-share option says it vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F4, F7 | 12,328 | $0.00 | $0.00 |
| Exercise | Stock Option F4, F8 | 5,101 | $0.00 | $0.00 |
| Exercise | Common Stock F4 | 12,328 | $8.33 | $103K |
| Exercise | Common Stock F4 | 5,101 | $2.22 | $11K |
| Sale | Common Stock F5 | 24,188 | $46.39 | $1.12M |
| Sale | Common Stock F6 | 5,654 | $46.39 | $262K |
| Sale | Common Stock F3 | 6,503 | $46.39 | $302K |
| Holding | Common Stock | -- | -- | -- |
| Sale | Common Stock F3 | 5,654 | $55.01 | $311K |
| Sale | Common Stock F3 | 6,503 | $55.01 | $358K |
| Sale | Common Stock F1 | 5,653 | $50.15 | $283K |
| Sale | Common Stock F3 | 6,503 | $50.15 | $326K |
| Sale | Common Stock F1 | 16,918 | $24.67 | $417K |
| Sale | Common Stock F1 | 16,918 | $25.00 | $423K |
| Sale | Common Stock F1, F2 | 16,918 | $24.40 | $413K |
Footnotes (8)
- F1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.
- F2. This transaction was executed in multiple trades at price ranging from $22.46 to $26.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026
- F4. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
- F5. Includes the sale of 6,759 shares of common stock held and the option exercise and sale of 17,429 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
- F6. The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
- F7. These stock options are fully exercisable.
- F8. The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average sale price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What price range applied to the February 20 HTFL sale?
What holding is listed for CR Asset Protection Trust of 2023?
AI-generated analysis. How Rhea-AI works. Not financial advice.